Clinical trials
Multiple Sclerosis, Relapsing-Remitting trials in Switzerland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
35 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 23 |
| Terminated | 5 |
| Active, not recruiting | 4 |
| Recruiting | 2 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biogen | 7 |
| Hoffmann-La Roche | 4 |
| University Hospital, Basel, Switzerland | 4 |
| Bayer | 3 |
| Novartis Pharmaceuticals | 3 |
| Claudio Gobbi | 2 |
| Amgen | 1 |
| Cantonal Hospital of St. Gallen | 1 |
| Cellerys AG | 1 |
| Chiara Zecca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis, Relapsing-Remitting | 35 |
| Multiple Sclerosis | 15 |
| Multiple Sclerosis, Chronic Progressive | 2 |
| Recurrence | 2 |
| Demyelinating Diseases | 1 |
| Diffuse Cerebral Sclerosis of Schilder | 1 |
| Lower Urinary Tract Symptoms | 1 |
| Neuromyelitis Optica | 1 |
| Urinary Bladder, Overactive | 1 |
Trials
Showing 26 to 35 of 35. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.